Clinical Trial Update: Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD) [Phase 2]

View source ↗

Summary

Phase 2 pilot study evaluating abatacept for safety and efficacy in adults and children 6+ with nephrotic syndrome due to FSGS or minimal change disease; trial …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Minimal Change Disease
• Nephrotic Syndrome

Drugs mentioned

• Abatacept (abatacept)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Nephrotic Syndrome, Focal Segmental Glomerulosclerosis | Phase 2 | Status: COMPLETED | Results posted: 2021-03-05